Rotavirus is a major cause of diarrhoea1 disease in young children and animals. Worldwide, it is responsible for 870,000 human deaths per year, primarily in the developing countries and causes significant economic losses in agriculture [I ,2] .
Natural infections in infancy prevent severe diarrhoea when subsequently challenged [3] . The current goal of rotavirus vaccination is to induce immunity which is at least as efficient as that elicited by natural infections [4] . To date all candidate rotavirus vaccines have failed in one or more aspects relating to safety, immunogenicity, or efficacy [ 1,2].
Vaccine development is preceding detailed characterisation of the mucosal humoral and cellular immune responses to rotavirus. Antibodies at the intestinal mucosa rather than in circulation are a prime protective factor and can mediate passive protection [5] . However, other protective immune mechanisms may be involved also and both cytotoxic lymphocytes and T helper cells have been demonstrated [6, 7] .
The aim of these experiments was to induce mucosal priming which would result in protection against subsequent challenge with rotavirus and to characterise the kinetics of both humoral and cellular aspects of this response.
Since rotaviruses are ubiquitous, gnotobiotic lambs were used as a model for mucosal priming of immunologically naive subjects. Immune stimulating complexes or ISCOMs have been demonstrated as potent and effective antigen delivery systems for mucosal immunisation and were used in this study as an adjuvant for inactivated rotavirus [8] .
either phosphate buffered saline (PBS) ( n 4 ) or inactivated bovine rotavirus (RV, pre-inactivation titre 106.8 fluorescent focus units (ffu)) (n=3) each with 500 18 ISCOM matrix. Lambs were monitored at regular intervals and challenged orally with lo8.' ffu of live lamb rotavirus at 21 days after initial priming. Lambs were killed at intervals after challenge. Determinations of specific and total IgA and IgG antibodies and virus-neutralising (VN) antibodies were made in serum, nasal secretions, and gut scrapings by ELISAs and virus neutralisation tests. Virus excretion in faeces was detected by SDS-PAGE. FACS analysis was performed to analyse changes in lymphocyte subpopulations. Rotavirus-specific IgA and IgG antibody-secreting cell (ASC) numbers were determined in lymphocyte populations isolated from peripheral blood (PBLs) and gut-associated lymphoid tissues. Group means were analysed by one-way analysis of variance.
Gnotobiotic lambs aged 6 days were immunised orally with Systemic priming was achieved in response to oral administration of RV with ISCOMs. This was seen as significantly increased virus-specific IgG ASCs ( Table 1) and antibody levels (Table 1) in peripheral blood at 7 and 1 I days after immunisation, together with a significant increase in the percentage of CD45R' cells (B cell marker) in peripheral blood (44.6% (40.9 %-49%) in RV group versus 18.7% (14.6%-21.5%) in PBS group; p<O.OOI) at 21 days after immunisation.
Following challenge, the vaccinated group cleared the virus in a significantly shorter period (5-6 days) than the non-vaccinated control group (8-10 days; p<O.Ool). Both groups mounted systemic immune responses showing increases in numbers of virus-specific IgA and IgG ASCs in the peripheral blood.
Mucosal priming was also achieved after a single oral dose with rotavirus and ISCOMs. Secretory immunity was demonstrated by increases in virus-specific IgA and IgG antibodies in nasal secretions (Table 2 ). In the vaccinated group, these increases were significantly higher than those in the non-vaccinated control group. In gut scrapings, the vaccinated group had a significantly higher level of virus-specific IgA than the control group (1085 units/Fg IgA versus 265 unitdFg IgA; p<O.OI).
Specific secretory antibodies were detected at the site of antigen delivery, the intestinal mucosa, and were also secreted at a distant (nasal) mucosal surface. This result is in keeping with the concept of a common mucosal immune system and provides a useful way of monitoring intestinal responses where repeated sampling is indicated. A specific IgA and IgG response with virus-neutralising activity was observed in serum in both groups but no neutralising activity was observed in secretions. In keeping with recent results of others [9] , this suggests that a mechanism of mucosal immune protection other than neutralising antibody may be primed by oral administration of inactivated virus and ISCOMs.
